Business Context and Reporting Period
This Form 8-K Current Report, dated March 25, 2022, details material agreements entered into by Axsome Therapeutics, Inc. The filing primarily concerns the acquisition of the sleep disorder treatment Sunosi from Jazz Pharmaceuticals and a concurrent amendment to the Company's existing credit facility with Hercules Capital, Inc.
Key Financial Metrics and Transaction Terms
Acquisition of Sunosi Assets
- Initial Purchase Price: $50,000,000.
- Inventory Payment: $3,000,000 for specified inventory.
- Royalty Obligations (U.S. Territory): High-single digit royalty for current indications; mid-single digit royalty for future indications.
- Assumed Milestones: Up to $165 million in revenue milestones and $1 million in development milestones payable to SK Biopharmaceuticals and Aerial Biopharma.
- Assumed Liabilities: Single-digit tiered royalties to SK and Aerial based on sales.
Debt Facility Amendment
- Tranche 1 Advance: Increased from $60,000,000 to $95,000,000.
- Tranche 2 Advances: Restructured into three sub-tranches of $35,000,000, $35,000,000, and $30,000,000.
- Tranche 3 Advance: Split into two sub-tranches of $15,000,000 and $5,000,000.
- Tranche 4 Advance: Decreased from $55,000,000 to $50,000,000.
- Tranche 5 Advance: Decreased from $75,000,000 to $35,000,000.
- Interest Rate Cap: Modified to not exceed 10.70% (floating rate based on greater of 8.95% or US WSJ Prime + 5.70%).
- Minimum Cash Requirement: Increased from $15,000,000 to $40,000,000 (reducible to $25,000,000 upon FDA approval of AXS-05).
- Equity Purchase: Agent to purchase between $5,000,000 and $8,000,000 of unregistered common stock at a price no less than a 20% discount to the three-day VWAP.
Note: This filing does not provide revenue, profit, cash flow, or margin data for the Company.
Material Changes and Transaction Structure
The Company entered into an Asset Purchase Agreement to acquire Sunosi, a dual-acting dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness. The transaction involves a two-stage closing:
- Initial Closing (U.S. Territory): Occurs within three business days after satisfaction of conditions, but no sooner than 40 days after signing (extendable by 5 days). Includes U.S. IP, contracts, inventory, and FDA approval.
- Sequential Closing (Ex-U.S. Territory): Occurs within 60 days of the U.S. closing. Includes EMA and UK MHRA marketing authorizations.
The debt amendment is conditioned upon the closing of the Sunosi acquisition and reflects the capital requirements for the transaction.
Guidance, Risks, and Contingencies
- Closing Conditions: The acquisition is subject to antitrust approval from the Federal Trade Commission (FTC) under the Hart-Scott-Rodino Act and receipt of specific financial statements from Jazz Pharmaceuticals.
- Termination: The Purchase Agreement includes customary termination provisions.
- Employee Retention: Axsome has agreed to extend employment offers to certain U.S. employees of the Sunosi business prior to closing.
- Representations: Investors are cautioned not to rely on representations and warranties in the agreement as characterizations of actual facts, as they were made only as of the agreement date.
Key Facts for Investor Verification
- Verify the status of the FTC antitrust approval required for the Sunosi acquisition closing.
- Confirm the exact timing of the initial U.S. closing and the subsequent ex-U.S. closing.
- Review the full text of the Second Amendment to the Loan and Security Agreement for detailed covenants and interest rate mechanics.
- Monitor the Company's cash position to ensure compliance with the new $40,000,000 minimum cash requirement.
- Assess the potential dilution impact from the $5,000,000 to $8,000,000 stock purchase by the lending agent.